Emtricitabine (Emtriva, FTC) is an antiviral medicine which decreases the body's amount of HIV. Emtricitabine on of Anti-HIV drugs slow down or protect the immune system against damage and reduce the risk of diseases related to developing of AIDS. Emtricitabine use also for treatment of hepatitis B virus. Emtricitabine is a drug class known as nucleoside reversing transcriptase inhibitors (NRTIs). In view of Emtricitabine's clinical significance, a thorough review of the physical and pharmaceutical characteristics and details of the multiple analytical techniques used to test the drug in pharmaceutical and biological systems was conducted. The methods investigated include identification test, Spectroscopy, chromatography, electrochemicals, and Thermal. Beside the analytical profile, the degradation and stability of Emtricitabine, its pharmacology and pharmacokinetics, Pharmaceutical Applications, Mechanism of Action, dosage forms and dose, ADME profile, and interactions have been debated.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/bs.podrm.2019.10.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Feasibility of implementing viral hepatitis services into a correctional service facility in Cape Town, South Africa.
Int J Drug Policy
January 2025
Division of Hepatology, Department of Medicine, Faculty of Health Sciences, University of Cape Town and Groote Schuur Hospital, Main Road, Observatory, Cape Town, South Africa. Electronic address:
Background: Hepatitis B virus (HBV) and hepatitis C virus (HCV) are estimated to be of the most prevalent infectious diseases in correctional settings worldwide. However, viral hepatitis services have not been routinely integrated into South African correctional facilities. We aimed to assess prevalence of HBV infection and HCV infection among people accessing HIV services and assess the feasibility of viral hepatitis service integration in a South African correctional centre.
View Article and Find Full Text PDFAssociation of nucleoside reverse transcriptase inhibitors with adverse perinatal outcomes in pregnant women living with HIV: systematic review and meta-analysis.
Clin Microbiol Infect
January 2025
Infectious Disease Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK. Electronic address:
Background: The World Health Organization (WHO) recommends antiretroviral therapy (ART) containing two nucleoside reverse transcriptase inhibitors (NRTIs) as backbone. WHO recommends tenofovir disoproxil fumarate combined with lamivudine or emtricitabine as first line in pregnancy, and zidovudine, abacavir or tenofovir alafenamide, combined with lamivudine or emtricitabine, as alternatives.
Objectives: Evaluate risk of adverse perinatal outcomes in pregnant women living with HIV (WLHIV) receiving different NRTIs.
Challenges in estimating the counterfactual placebo HIV incidence rate from a registration cohort: The PrEPVacc trial.
Clin Trials
December 2024
Medical Research Council Clinical Trials Unit, University College London, London, UK.
Background: There is increasing recognition that the interpretation of active-controlled HIV prevention trials should consider the counterfactual placebo HIV incidence rate, that is, the rate that would have been observed if the trial had included a placebo control arm. The PrEPVacc HIV vaccine and pre-exposure prophylaxis trial (NCT04066881) incorporated a pre-trial registration cohort partly for this purpose. In this article, we describe our attempts to model the counterfactual placebo HIV incidence rate from the registration cohort.
View Article and Find Full Text PDFEfficacy of dolutegravir plus lamivudine in treatment-naive people living with HIV without baseline drug-resistance testing available (D2ARLING): 48-week results of a phase 4, randomised, open-label, non-inferiority trial.
Lancet HIV
January 2025
Fundación IDEAA, Buenos Aires, Argentina.
Background: Dolutegravir plus lamivudine has emerged as a preferred treatment for HIV; however, initiating this regimen without baseline resistance testing raises concerns about the potential presence of pretreatment lamivudine resistance. We aimed to evaluate the efficacy of dolutegravir plus lamivudine in the absence of information on baseline resistance testing in treatment-naive people with HIV.
Methods: We did an open-label, non-inferiority, single-centre, phase 4, randomised controlled study (D2ARLING), designed to assess the efficacy and safety of dolutegravir plus lamivudine in treatment-naive people with HIV with no available baseline resistance testing.
A Cross-Biomeasure Study to Optimize Antiretroviral Adherence Estimation.
J Acquir Immune Defic Syndr
November 2024
University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC, USA.
Background: Incomplete adherence to daily tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) reduces effectiveness. Adherence biomeasures (i.e.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!